RNXT stock forecast, quote, news & analysis
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment... Show more
Why RenovoRx (RNXT) Stock Is Down -10% in the Last 30 Days
Key Takeaways
- RenovoRx (RNXT) shares pulled back roughly 10% over the past 30 days, easing from about $1.55 to $1.39, after peaking near $2.52 in early September.
- The decline largely reflects profit-taking and consolidation following a sharp multi-month rally rather than any single negative catalyst.
- Over the trailing quarter, the stock remains up approximately 44%, extending a run that began near $0.96 in late July.
- The company continues advancing its Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine for locally advanced pancreatic cancer, with final data expected in 2027.
- Commercialization of the FDA-cleared RenovoCath device is scaling, supported by an oversubscribed $10 million private placement completed earlier in 2026.
- Third-quarter 2026 results scheduled for early November and trial-enrollment milestones are key near-term catalysts for the stock.
- For more detail on valuation and catalysts, explore Price Targets, Earnings, and Forecast pages.
- Explore Trending AI Robots to see AI-driven trading strategies applied across the market.
RenovoRx (RNXT) Company Overview and Market Position
RenovoRx, Inc. is a Mountain View, California-based life sciences company developing targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared local drug-delivery device. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform is designed to deliver therapeutic agents directly across the arterial wall near a tumor site, with the goal of bathing the target tumor while potentially reducing toxicities compared with systemic intravenous therapy.
The company's lead program, intra-arterial gemcitabine (IAG) delivered via RenovoCath, is being evaluated in the ongoing Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. RenovoCath with gemcitabine holds Orphan Drug Designation for pancreatic cancer and bile duct cancer. In parallel, RenovoRx is building commercial revenue from standalone RenovoCath device sales, which reached roughly $1.1 million for full-year 2025. Investors follow the stock for its combination of a real device revenue stream and a high-value, late-stage oncology pipeline.
RenovoRx (RNXT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RNXT has declined approximately 10%, moving from a close near $1.55 to around $1.39. The decline was not a straight line: the stock had surged to an intraday high near $2.59 in early September before giving back gains, and the trailing month reflects a gradual retreat into the low $1.30s to low $1.40s range.
The broader quarterly picture is materially different. From a base near $0.96 in late July, shares climbed roughly 44% to their current level, driven by a sharp August-to-early-September advance. In other words, the stock remains in an overall uptrend on a multi-month basis, even as the most recent 30 days show a meaningful pullback from the September peak.
What Drove RNXT Stock Price in the Last 30 Days
The 30-day decline appears tied primarily to profit-taking and consolidation after an unusually sharp run-up, rather than a single identifiable negative event. Micro-cap, clinical-stage biotech names often experience elevated volatility, and RNXT's surge from under $1.00 in late July to more than $2.50 in early September created conditions for a technical pullback.
Notably, the pullback occurred even as the company reported constructive developments. In October, RenovoRx announced the first patient enrolled in the PRISM-TAMP investigator-initiated trial exploring TAMP in borderline resectable pancreatic cancer, and researchers published a peer-reviewed case series highlighting the TAMP platform's potential in locally advanced pancreatic cancer. The absence of a clear adverse catalyst suggests the recent move reflects normal price discovery and reduced speculative momentum rather than a deterioration in fundamentals.
What Drove RNXT Stock Performance Over the Last Quarter
The quarterly advance was supported by a combination of strengthening fundamentals and growing institutional interest. Early in the year, RenovoRx closed an oversubscribed $10 million private placement, which management said reflected strong institutional demand and reinforced the balance sheet as cash rose to approximately $12.4 million as of March 31, 2026.
Operationally, the company reported accelerating RenovoCath commercialization, with first-quarter 2026 revenue of $563,000 versus $197,000 a year earlier, and reiterated that TIGeR-PaC enrollment was on track to complete by mid-2026 with final data expected in 2027. Additional recognition, including being named to Fast Company's "World's Most Innovative Companies of 2026" list in the Medical Devices category, and a positive pharmacokinetic abstract presented at the 2026 ASCO Gastrointestinal Cancers Symposium, helped sustain investor attention. Analysts tracked by major financial data providers assign RNXT a consensus "Strong Buy" rating, which has contributed to a supportive sentiment backdrop.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's automated trading strategies. Tickeron provides hundreds of AI-driven trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. The featured robots span a range of strategies, timeframes, and performance metrics, allowing users to compare approaches based on their own objectives and risk tolerance. For traders looking to supplement their research on names like RNXT with data-driven, rules-based signals, the page serves as a practical starting point for exploring automated trading ideas.
RNXT Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape RNXT's trajectory in the months ahead. The company's third-quarter 2026 financial results, scheduled for early November, will offer an updated read on RenovoCath revenue momentum, cash position, and operating expenses. Progress on the Phase III TIGeR-PaC trial remains the central long-term catalyst, with completion of the 114-patient enrollment targeted for mid-2026 and final data anticipated in 2027.
Investors should also monitor further commercialization milestones, including new and repeat RenovoCath orders across U.S. cancer centers, as well as data emerging from investigator-initiated trials such as PRISM-TAMP. As with any clinical-stage biotech, execution risk, cash burn, and regulatory and clinical-trial outcomes remain key uncertainties. This information is intended to inform, not to serve as investment advice or a prediction of future price performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RNXT's RSI Oscillator ascends from oversold territory
The RSI Oscillator for RNXT moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 30 of the 33 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 59 of 70 cases where RNXT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
Following a +3.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNXT advanced for three days, in 200 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNXT as a result. In 83 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for RNXT turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
RNXT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RNXT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RNXT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RNXT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. RNXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.680) is normal, around the industry mean (3.498). P/E Ratio (-3.645) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (31.250) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology